Core Insights - Intuitive has received FDA clearance for its latest advanced energy instrument, the Vessel Sealer Curved, designed for use with its multiport da Vinci systems [1][2] - The Vessel Sealer Curved is the first of Intuitive's advanced energy instruments cleared for the transection of lymphatic vessels, enhancing its multifunctionality and precision [2][4] Product Features - The Vessel Sealer Curved features a slim, curved jaw that follows anatomical contours, improving visibility and control in tight spaces [3] - It is designed for grasping, blunt dissection of tissue, bipolar coagulation, and mechanical transection of blood vessels up to 7mm in diameter, as well as lymphatic vessels [4] Company Background - 2025 marks the 30th anniversary of Intuitive in developing robotic-assisted technology, with nearly 17 million da Vinci procedures performed and around 90,000 surgeons trained [5] - Intuitive aims to improve patient outcomes, enhance care team experiences, increase access to minimally invasive care, and reduce treatment costs [5][6] Technology Overview - The da Vinci surgical systems provide high-definition 3D vision and robotic assistance, enabling precise dissection and reconstruction during minimally invasive surgeries [7]

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant milestone in the field of robotic surgery [2][3][5] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [2][7] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [7] Surgical Procedure Details - The telesurgery involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, which are advanced bariatric procedures aimed at long-term weight loss and improved metabolic health [4][8] - The surgeries were performed remotely over a distance of 560 miles, showcasing the capabilities of the SSi Mantra 3 system with zero perceptible lag and flawless precision [3][8] Technological Advancements - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities, supporting various surgical specialties [11] - The system has been clinically validated in over 100 different types of surgical procedures in India, demonstrating its versatility and effectiveness [11] Vision and Impact - The company emphasizes its mission to democratize robotic surgery, bridging healthcare gaps and making advanced surgical care accessible to remote regions [5][6] - SS Innovations aims to redefine surgical care access, equity, and excellence through its innovative technologies and humanitarian vision [6]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant advancement in robotic surgery technology [1][4] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [5] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [5] Technological Achievement - The robotic telesurgery bridged a distance of 560 miles between Gurugram and Indore, India, performed with zero perceptible lag and flawless precision [2][7] - The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, showcasing the capabilities of the SSi Mantra 3 system [3][7] Leadership Commentary - Dr. Sudhir Srivastava, CEO, emphasized that this achievement bridges healthcare gaps and makes advanced surgical expertise accessible to remote regions [4] - Dr. Mohit Bhandari, who led the surgery, highlighted the potential of robotic telesurgery to redefine surgical care and improve access to healthcare [4] Future Vision - SS Innovations aims to continue refining its technology to enhance surgical efficiency and improve patient outcomes, particularly in underserved areas [4]

CAESAREA, Israel, July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's ordinary shares, no par value per share ...

Core Insights - OraSure Technologies, Inc. has launched the HEMAcollect™ ● PROTEIN product aimed at enhancing proteomic research through improved sample collection and preservation [1][2] - The HEMAcollect™ ● PROTEIN is an evacuated blood collection tube designed to stabilize plasma proteins for up to seven days, addressing limitations of traditional blood collection methods [1][2] - The product is expected to provide operational and financial efficiencies for proteomic researchers, facilitating high-quality data generation [1] Product Features - The HEMAcollect™ ● PROTEIN BCT utilizes ProteoPrecision™ technology to minimize hemolysis and platelet activation, ensuring sample integrity [2] - It is compatible with various proteomic technologies, including mass spectrometry and immunoassays, making it versatile for different research applications [2] Company Overview - OraSure Technologies focuses on transforming healthcare through innovative diagnostic tests and sample management solutions, serving a wide range of customers including clinical laboratories and pharmaceutical companies [4] - DNA Genotek, a subsidiary of OraSure, specializes in developing products that optimize sample collection and performance for high-quality biological samples [5]

Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025.InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data a ...

Group 1: Stock Performance - CRISPR Therapeutics AG shares increased by 9.6% to close at $60.08, with notable trading volume compared to typical sessions [1] - The stock has gained 27.7% over the past four weeks, indicating strong investor interest [1] Group 2: Pipeline Developments - The rise in CRISPR's stock price is attributed to positive sentiment regarding its pipeline, particularly the in vivo candidate CTX310 targeting ANGPTL3 for atherosclerotic heart disease [2] - Updated data from an early-stage study showed a single dose of CTX310 resulted in peak reductions of up to 82% in triglyceride levels and up to 86% in LDL levels, generating excitement for other pipeline candidates [2] Group 3: Financial Expectations - The company is expected to report a quarterly loss of $1.54 per share, reflecting a year-over-year change of -3.4%, while revenues are projected at $5.89 million, a significant increase of 1032.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [4] Group 4: Industry Context - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences also operates, closing the last trading session 10.8% higher at $7.7 [4] - Wave Life Sciences has seen a consensus EPS estimate change of -6.6% over the past month, indicating a potential decline in performance compared to the previous year [5]

Core Viewpoint - The article discusses the launch of the 2025 Beijing Key Laboratory application process, emphasizing its alignment with the construction of the Beijing International Science and Technology Innovation Center and focusing on key industries and cutting-edge technology fields [1][10]. Group 1: Application Focus Areas - The application areas for the Beijing Key Laboratories include new generation information technology (such as AI, big data, 5G/6G communication), medical health (including biomedicine, medical devices, precision medicine), intelligent manufacturing and equipment (covering industrial internet, intelligent robotics, high-end equipment manufacturing), new materials (like high-performance materials, nanomaterials, new energy materials), new energy (including clean energy, energy storage technology, carbon neutrality-related technologies), and agricultural technology [1][2]. Group 2: Application Conditions and Requirements - The applicant units must be registered enterprises, institutions, or social organizations in Beijing. Enterprises must meet specific sales revenue and R&D investment criteria. For joint laboratories, one unit must be designated as the leading unit, with others as co-construction units, and a co-construction agreement must be signed [3]. - Research directions should focus on scientific issues within the application areas, highlighting technological innovation, industry relevance, and potential for results implementation. The research team must consist of high-level researchers with solid foundations or achievements in relevant fields [4]. Group 3: Application Process and Timeline - The application notification for the Beijing Key Laboratories was released on April 9, 2025, with the specific deadline for submissions to be announced later. Required materials include the "Beijing Key Laboratory Application Form" and supporting documents (such as unit qualifications, research achievements, team introductions). The evaluation will be conducted by an expert committee, focusing on the project's innovation, feasibility, industrial value, and support for Beijing's technological innovation [6][5]. Group 4: Policy Support for Intelligent Manufacturing - Beijing has significantly increased support for the intelligent manufacturing sector, with recent developments including the establishment of a key laboratory for intelligent manufacturing, focusing on cutting-edge technologies (like industrial internet, intelligent detection, standard systems) and key common technologies (such as measurement, certification, and testing) [7]. - Collaborative innovation between industry, academia, and research institutions is encouraged to promote technology transfer and upgrade the industrial chain [7]. Group 5: Application Recommendations - Applications should focus on critical needs within the intelligent manufacturing sector, particularly on "bottleneck" technologies (such as high-end sensors, industrial software, precision processing equipment). Strengthening collaboration across the industry chain, including upstream and downstream enterprises, universities, and research institutions, is recommended to form a collaborative innovation network [8]. - Application materials should demonstrate the potential for industrialization of technological achievements, such as patent layouts, standard formulation, and demonstration applications. Consulting professional institutions for application guidance is advised to enhance material quality [8]. Group 6: Reference Cases - The High-Entropy Energy Materials and Devices Beijing Key Laboratory is currently accepting applications, focusing on energy materials research, which can serve as a reference for application processes and management requirements. The Smart Traditional Chinese Medicine Chronic Disease Prevention and Treatment Beijing Key Laboratory explores chronic disease prevention technologies through the integration of AI and traditional Chinese medicine, showcasing interdisciplinary research [9].

Company Overview - DaVita HealthCare (DVA) closed at $141.84, down 1.36% from the previous trading session, underperforming the S&P 500 which gained 0.61% [1] - Prior to this trading day, DVA shares had increased by 3.37%, outperforming the Medical sector's decline of 0.67% but lagging behind the S&P 500's rise of 3.85% [1] Financial Performance Forecast - DaVita is expected to report an EPS of $2.7, reflecting a 4.25% increase from the same quarter last year [2] - Revenue is forecasted to be $3.3 billion, indicating a 3.5% growth compared to the same quarter last year [2] - For the full year, analysts anticipate earnings of $10.76 per share and revenue of $13.48 billion, representing increases of 11.16% and 5.15% respectively from the previous year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for DaVita are important as they indicate changing near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks DaVita as 3 (Hold), with the consensus EPS estimate remaining unchanged over the past month [6] Valuation Metrics - DaVita's Forward P/E ratio is 13.37, which is lower than the industry average Forward P/E of 18.96, indicating a valuation discount [7] - The company has a PEG ratio of 0.99, compared to the industry average PEG ratio of 1.8, suggesting that DVA is relatively undervalued based on its expected earnings growth [8] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita, has a Zacks Industry Rank of 39, placing it in the top 16% of over 250 industries [9]